Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blinded, Placebo-Controlled Trial
View ORCID ProfileSrinivas Shenoy, View ORCID ProfileSagar Munjal, View ORCID ProfileSarah Al Youha, View ORCID ProfileMohammad Alghounaim, View ORCID ProfileSulaiman Almazeedi, View ORCID ProfileYousef Alshamali, View ORCID ProfileRichard H Kaszynski, View ORCID ProfileSalman Al-Sabah, Kuwait Clinical Trial Group
doi: https://doi.org/10.1101/2021.11.08.21265884
Srinivas Shenoy
1Dr Reddy’s Laboratories Limited, 8-2-337, Road No.3, Banjara Hills, Hyderabad-500 034, India; Email:
Sagar Munjal
2Dr Reddy’s Laboratories Limited, 8-2-337, Road No.3, Banjara Hills, Hyderabad-500 034, India; Email:
Sarah Al Youha
3Jaber Al-Ahmad Al-Sabah Hospital, Kuwait, Khalid Ben AbdulAziz Street, South Surra-47781, Kuwait; Email:
Mohammad Alghounaim
4Jaber Al Ahmad Hospital at Mishref Field Hospital, Mubarak Al-Abdullah Street, Mishref-90005, Kuwait; Email:
Sulaiman Almazeedi
5Jaber Al Ahmad Hospital at Mishref Field Hospital, Mubarak Al-Abdullah Street, Mishref-90005, Kuwait; Email:
Yousef Alshamali
6Jaber Al Ahmad Hospital at Mishref Field Hospital, Mubarak Al-Abdullah Street, Mishref-90005, Kuwait; Email:
Richard H Kaszynski
7Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, 2-34-10, Ebisu, Shibuya-ku, Tokyo 150-0013, Japan; Email:
Salman Al-Sabah
8Jaber Al Ahmad Hospital at Mishref Field Hospital, Mubarak Al-Abdullah Street, Mishref-90005, Kuwait; Email:
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Posted November 09, 2021.
Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blinded, Placebo-Controlled Trial
Srinivas Shenoy, Sagar Munjal, Sarah Al Youha, Mohammad Alghounaim, Sulaiman Almazeedi, Yousef Alshamali, Richard H Kaszynski, Salman Al-Sabah, Kuwait Clinical Trial Group
medRxiv 2021.11.08.21265884; doi: https://doi.org/10.1101/2021.11.08.21265884
Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blinded, Placebo-Controlled Trial
Srinivas Shenoy, Sagar Munjal, Sarah Al Youha, Mohammad Alghounaim, Sulaiman Almazeedi, Yousef Alshamali, Richard H Kaszynski, Salman Al-Sabah, Kuwait Clinical Trial Group
medRxiv 2021.11.08.21265884; doi: https://doi.org/10.1101/2021.11.08.21265884
Subject Area
Subject Areas
- Addiction Medicine (325)
- Allergy and Immunology (638)
- Anesthesia (169)
- Cardiovascular Medicine (2426)
- Dermatology (208)
- Emergency Medicine (383)
- Epidemiology (11853)
- Forensic Medicine (10)
- Gastroenterology (706)
- Genetic and Genomic Medicine (3807)
- Geriatric Medicine (353)
- Health Economics (643)
- Health Informatics (2442)
- Health Policy (945)
- Hematology (346)
- HIV/AIDS (800)
- Medical Education (374)
- Medical Ethics (105)
- Nephrology (406)
- Neurology (3562)
- Nursing (201)
- Nutrition (534)
- Oncology (1848)
- Ophthalmology (542)
- Orthopedics (224)
- Otolaryngology (291)
- Pain Medicine (235)
- Palliative Medicine (68)
- Pathology (453)
- Pediatrics (1048)
- Primary Care Research (425)
- Public and Global Health (6229)
- Radiology and Imaging (1307)
- Respiratory Medicine (841)
- Rheumatology (384)
- Sports Medicine (328)
- Surgery (412)
- Toxicology (51)
- Transplantation (174)
- Urology (148)